* NATCO Pharma announced the conclusion of the US FDA inspection at its API manufacturing plant in Manali, Chennai. * The inspection was conducted from November 17th to November 21st, 2025. * The company received seven observations in Form-483 upon conclusion of the inspection. * NATCO believes the observations are procedural and is confident in addressing them comprehensively. * The company remains committed to cGMP compliance and supplying high-quality products.
